Same Indication

Ipilimumab vs Lutetium Lu-177 Vipivotide Tetraxetan

Ipilimumab vs Lutetium Lu-177 Vipivotide Tetraxetan: Overview

This comparison examines the pharmacological differences between Ipilimumab and Lutetium Lu-177 Vipivotide Tetraxetan.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days.

Chemical Properties

Type: Ipilimumab — Antibody; Lutetium Lu-177 Vipivotide Tetraxetan — Protein.